Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Anshuman P. Malaviya"'
Autor:
Jane How, Denise Rosembert, Tim Raine, Maria Roe, Deepak R. Jadon, Pippa Herbert, Cristina Garcia-Sueiro, Jacqueline Tomlinson, Paul Norris, Julien Magsino, Fiona Toh, Anshuman P. Malaviya, Allison Nightingale
Publikováno v:
Posters.
Introduction Biosimilar adalimumab became available in the UK in October, 2018, with payers introducing a series of measures to drive the adoption of the ‘best value’ adalimumab1. Consideration of value should include risk of loss of efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ccf79fcf7c881e79ee63826d81ef3cd
https://doi.org/10.1136/gutjnl-2020-bsgcampus.216
https://doi.org/10.1136/gutjnl-2020-bsgcampus.216
Autor:
Christopher Holroyd, Susan Smolen, A E Litwic, Anshuman P. Malaviya, Christopher Chan, Muriel Green, Jennifer Humphreys, Claire Holmes, Sarah Bennett, Elizabeth M Curtis, Jo Ledingham, Joanne Topliffe, Mohammed A Yusuf, Rakhi Seth, Marwan Bukhari
Publikováno v:
Rheumatology. 58:220-226
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e39b43937f0644d6b9b88fff725d2ca7
https://doi.org/10.1093/rheumatology/key207
https://doi.org/10.1093/rheumatology/key207
Autor:
D Rosembert, A Nightingale, P Herbert, Tim Raine, F Toh, C Garcia-Sueiro, M Roe, J Magsino, J Thomas, A Negoescu, Deepak R. Jadon, Anshuman P. Malaviya, J How, Paul Norris, J Tomlison
Publikováno v:
Journal of Crohn's and Colitis. 14:S438-S439
Background Biosimilar adalimumab became available in the UK in October 2018, with payers introducing a series of measures to drive the adoption of the ‘best value’ adalimumab.1 Consideration of value should include risk of loss of efficacy and ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43b93c70dfdc57cc7eff7bcc2c0625f2
https://doi.org/10.1093/ecco-jcc/jjz203.634
https://doi.org/10.1093/ecco-jcc/jjz203.634
Autor:
Jo Ledingham, A E Litwic, Elizabeth M Curtis, Jennifer Humphreys, Christopher Holroyd, Rakhi Seth, Marwan Bukhari, Muriel Green, Joanne Topliffe, Anshuman P. Malaviya, Mohammed A Yusuf, Sarah Bennett, Claire Holmes, Susan Smolen, Christopher Chan
Publikováno v:
Humphreys, J 2019, ' The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. ', Rheumatology (Oxford), vol. 58, no. 2, pp. e3-e42 . https://doi.org/10.1093/rheumatology/key208
The use of biologic therapies has transformed the management of inflammatory arthritis (IA). In contrast to conventional systemic DMARDs (csDMARDs) traditionally used to treat inflammatory disease, these agents offer a targeted approach, and their wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc98c60df1bcae57f8c41009bb24cc51
http://www.scopus.com/inward/record.url?scp=85056120706&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85056120706&partnerID=8YFLogxK
Autor:
John D. Fitzpatrick, Andrew J. K. Östör, Andrew Badcock, Calum T. Goudie, Andra Negoescu, Anshuman P. Malaviya, Elena Nikiphorou
Publikováno v:
Clinical rheumatology. 33(5)
Methotrexate (MTX) has become the first-line treatment for rheumatoid (RA) and psoriatic arthritis (PsA); however, few studies have focused on its tolerability. The objective of our analyses was to study RA and PsA patients in whom MTX was discontinu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8678c40a0dd62e37518c6693fdaa0347
https://pubmed.ncbi.nlm.nih.gov/24609758
https://pubmed.ncbi.nlm.nih.gov/24609758
Autor:
Anshuman P, Malaviya, Frances C, Hall
Publikováno v:
The Practitioner. 256(1747)
Chronic inflammatory rheumatological conditions are associated with an increased burden of cardiovascular disease (CVD). In both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) most excess mortality is cardiovascular. Increased CVD r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dfe904323be76836ad67b172bdf014df
https://pubmed.ncbi.nlm.nih.gov/22720456
https://pubmed.ncbi.nlm.nih.gov/22720456
Publikováno v:
Inflammopharmacology. 20(2)
Biologic disease modifying anti-rheumatic drugs have transformed the management of rheumatoid arthritis (RA) since their introduction into clinical practice over a decade ago. Following large-scale clinical trials, a number of biologics, with differe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5a2ce6a6c8e333b9e3290dd7fdbf28
https://pubmed.ncbi.nlm.nih.gov/22366810
https://pubmed.ncbi.nlm.nih.gov/22366810
Publikováno v:
Patient preference and adherence
Major advances in drug development have led to the introduction of biologic disease- modifying drugs for the treatment of rheumatoid arthritis, which has resulted in unprecedented improvement in outcomes for many patients. These agents have been foun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fd485e599302225121abffa62e8b21c
https://doi.org/10.2147/ppa.s23786
https://doi.org/10.2147/ppa.s23786
Publikováno v:
Arthritis & Rheumatism. 64:2403-2403
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b2c0631f01d7d38332aa0d31fb90e0
https://doi.org/10.1002/art.34487
https://doi.org/10.1002/art.34487